Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06406348 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT06406348 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 53 participants.
The verdict
NCT06406348, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.
Interventions
- OTHER Placebo
- DRUG ALIA-1758
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2025-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06406348
The ClinicalTrials.gov registry entry for NCT06406348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06406348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06406348 about?
NCT06406348 is a clinical study titled "A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants". This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.
What is the current status of trial NCT06406348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2024-05-09. Estimated completion is 2025-04-22.
What interventions are being tested in trial NCT06406348?
The interventions under investigation include: Placebo (OTHER), ALIA-1758 (DRUG).
Who is sponsoring clinical trial NCT06406348?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.